MedPath

Assessment of Combined CCM and ICD Device in HFrEF

Not Applicable
Recruiting
Conditions
Heart Failure
Heart Failure With Reduced Ejection Fraction
Implantable Defibrillator User
CCM Therapy
Non-ischemic Cardiomyopathy
Ischemic Cardiomyopathy
Sudden Cardiac Arrest
Arrhythmias, Cardiac
Ventricular Tachycardia
Ventricular Fibrillation
Interventions
Device: OPTIMIZER® Integra CCM-D System (Treatment Arm)
Registration Number
NCT05855135
Lead Sponsor
Impulse Dynamics
Brief Summary

The goal of this clinical trial is to demonstrate that the OPTIMIZER® Integra CCM-D System (the "CCM-D System") can safely and effective convert induced ventricular fibrillation (VF) and spontaneous ventricular tachycardia and/or ventricular fibrillation (VT/VF) episodes in subjects with Stage C or D heart failure who remain symptomatic despite being on guideline-directed medical therapy (GDMT), are not indicated for cardiac resynchronization therapy (CRT), and have heart failure with reduced left ventricular ejection fraction (LVEF ≤40%).

Eligible subjects will be implanted with the CCM-D System. A subset of subjects will be induced into ventricular fibrillation "on the table" in the implant procedure room. During the follow-up period, inappropriate shock rate and device-related complications will be evaluated. The follow-up period is expected to last at least two years.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
300
Inclusion Criteria

Individuals must meet all the following:

  1. Patient is aged 18 years or older;
  2. Patient meets the Stage C or D criteria of the Universal Definition of Heart Failure ;
  3. Patient has HFrEF (LVEF ≤40%);
  4. Patient is on GDMT for heart failure;
  5. Patient has a Class I or Class II indication for an ICD
  6. Patient has a reasonable expectation of meaningful survival of > 1 year;
  7. Patient has either non-ischemic cardiomyopathy or ischemic cardiomyopathy and is at least 40 days post-MI, if an MI occurred;
  8. Patient is willing to give informed consent, available for scheduled study follow-up visits, and able to complete all testing described in the study protocol at the investigational site location.
Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Patients should not have severe AI or AS, and should not have MS; additionally, patients undergoing DE testing should not have severe MR;
  2. Patients who have undergone mitral valve repair or clip within 90 days prior to study consent;
  3. Cardiac surgery within 90 days or a PCI procedure within 30 days prior to study consent;
  4. Prior heart transplant or ventricular assist device;
  5. Implanted mechanical tricuspid valve;
  6. PR interval greater than 375ms or advanced AV block;
  7. In situ S-ICD, pacemaker, or CRT device;
  8. Indicated for CRT;
  9. End stage renal disease, currently on dialysis, or with other major medical disorder (e.g. liver failure, terminal cancer);
  10. Indicated for permanent bradyarrhythmia pacing;
  11. Unstable angina pectoris within 30 days prior to study consent;
  12. Pregnant or planning to become pregnant during the study;
  13. Participating in another cardiac investigational device or drug study at the same time (or within 30 days prior to study consent); Note: Registries and other observational studies are acceptable.
  14. Other criteria that preclude Optimizer INTEGRA CCM-D implantation and/or CCM therapy, as determined by Investigator.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
CCM-D ImplantOPTIMIZER® Integra CCM-D System (Treatment Arm)The subject is implanted with the CCM-D device.
Primary Outcome Measures
NameTimeMethod
Device-related Complications (Primary Safety Objective)Implant to 6 months

Evaluate device-related complications through 6-months (excluding lead-related complications).

Device Effectiveness in Converting Induced Ventricular Fibrillation (Primary Efficacy Objective)Implant

Evaluate the device effectiveness in converting induced VF at the time of implantation.

Secondary Outcome Measures
NameTimeMethod
Inappropriate Shock Rate out to 6-months (Secondary Safety Objective)Implant to 6 months

Evaluate the incidence of inappropriate ICD shocks through the time when the last subject enrolled completes the 6-month visit.

Trial Locations

Locations (61)

Phoenix Heart

🇺🇸

Phoenix, Arizona, United States

CardioVascular Associates of Mesa

🇺🇸

Mesa, Arizona, United States

Chan Heart Rhythm Institute

🇺🇸

Mesa, Arizona, United States

Southwest Cardiovascular Associates

🇺🇸

Mesa, Arizona, United States

Arizona Heart Rhythm

🇺🇸

Phoenix, Arizona, United States

CVC Cardiovascular Consultants

🇺🇸

Phoenix, Arizona, United States

Honor Health

🇺🇸

Scottsdale, Arizona, United States

University of Southern California

🇺🇸

Los Angeles, California, United States

Cedars Sinai Medical Center

🇺🇸

Los Angeles, California, United States

Aurora Denver Cardiology Associates

🇺🇸

Aurora, Colorado, United States

Hartford HealthCare

🇺🇸

Hartford, Connecticut, United States

Broward Health Medical Center

🇺🇸

Fort Lauderdale, Florida, United States

Mount Sinai Medical Center Miami Beach

🇺🇸

Miami Beach, Florida, United States

Baptist Health South Florida

🇺🇸

Miami, Florida, United States

Advent Health Orlando

🇺🇸

Orlando, Florida, United States

Cleveland Clinic Weston

🇺🇸

Weston, Florida, United States

University of Kansas Medical Center

🇺🇸

Kansas City, Kansas, United States

Baptist Health Lexington

🇺🇸

Lexington, Kentucky, United States

Ochsner Medical Center

🇺🇸

Baton Rouge, Louisiana, United States

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

Saint Luke's Hospital

🇺🇸

Kansas City, Missouri, United States

Saint Luke's Mid America Heart Institute

🇺🇸

Kansas City, Missouri, United States

St. Louis VA

🇺🇸

Saint Louis, Missouri, United States

St. Louis Heart and Vascular

🇺🇸

St. Louis, Missouri, United States

University of Nebraska Omaha

🇺🇸

Omaha, Nebraska, United States

Virtua

🇺🇸

Cherry Hill, New Jersey, United States

Hackensack University Medical Center

🇺🇸

Hackensack, New Jersey, United States

The Heart House - Cardiovascular Associates of the Delaware Valley

🇺🇸

Haddon Heights, New Jersey, United States

Rutgers New Jersey Medical School

🇺🇸

Newark, New Jersey, United States

NYU Langone

🇺🇸

New York, New York, United States

Mount Sinai New York

🇺🇸

New York, New York, United States

Columbia University Medical Center / NewYork-Presbyterian

🇺🇸

New York, New York, United States

Weill Cornell Medicine

🇺🇸

New York, New York, United States

University of North Carolina

🇺🇸

Chapel Hill, North Carolina, United States

Sanger Heart and Vascular Institute

🇺🇸

Charlotte, North Carolina, United States

Cleveland Clinic

🇺🇸

Cleveland, Ohio, United States

The Ohio State University Wexner Medical Center

🇺🇸

Columbus, Ohio, United States

St. Francis Tulsa

🇺🇸

Tulsa, Oklahoma, United States

Portland VA Medical Center

🇺🇸

Portland, Oregon, United States

St. Luke's Bethlehem

🇺🇸

Bethlehem, Pennsylvania, United States

Bryn Mawr Medical Specialists Association

🇺🇸

Bryn Mawr, Pennsylvania, United States

Lancaster General Hospital

🇺🇸

Lancaster, Pennsylvania, United States

Penn Presbyterian

🇺🇸

Philadelphia, Pennsylvania, United States

Temple University

🇺🇸

Philadelphia, Pennsylvania, United States

Allegheny General Hospital

🇺🇸

Pittsburgh, Pennsylvania, United States

University of Pittsburgh Medical Center

🇺🇸

Pittsburgh, Pennsylvania, United States

Prisma Health

🇺🇸

Greenville, South Carolina, United States

Stern Cardiovascular Foundation

🇺🇸

Germantown, Tennessee, United States

Texas Cardiac Arrhythmia Research Foundation

🇺🇸

Austin, Texas, United States

Medical City Dallas

🇺🇸

Dallas, Texas, United States

UT Southwestern

🇺🇸

Dallas, Texas, United States

Medical City Fort Worth

🇺🇸

Fort Worth, Texas, United States

Houston Methodist

🇺🇸

Houston, Texas, United States

Houston VA Hospital

🇺🇸

Houston, Texas, United States

Christus Trinity Clinic

🇺🇸

Tyler, Texas, United States

Centra Health

🇺🇸

Lynchburg, Virginia, United States

Chippenham Hospital

🇺🇸

Richmond, Virginia, United States

Virginia Commonwealth University

🇺🇸

Richmond, Virginia, United States

Seattle VA

🇺🇸

Seattle, Washington, United States

Swedish

🇺🇸

Seattle, Washington, United States

Aurora St. Luke's Medical Center

🇺🇸

Milwaukee, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath